INTRODUCTION
Inflammatory bowel disease (IBD) reflects a spectrum of intestinal disorders, principally Crohn's disease (CD) and ulcerative colitis (UC), characterized by a dysregulated immune response to environmental and microbial antigens in genetically susceptible individuals (1) . Although the characteristics of intestinal inflammation define the IBD phenotype, extraintestinal manifestations (EIMs) of IBD frequently reveal distinct features underlying the immune disorder. IBD-associated spondyloarthritis (SpA), which includes both axial spinal inflammation and peripheral joint manifestations of synovitis, dactylitis, and enthesitis, is one of the most common EIMs of IBD (2) . Peripheral manifestations alone carry a prevalence of 20% in CD and 10% in UC, predominantly affecting joints of the lower limbs (3) . Clinical evidence linking intestinal inflammation with SpA (3) (4) (5) implicates the intestine as the source of aberrant systemic joint inflammation (6, 7) . The independent identification of genetic variants in the IL23R locus in both IBD (8) and SpA (9) reinforces the biologic underpinnings of this association by highlighting a potential shared role for interleukin-23 (IL-23)-dependent inflammation. Collectively, these data suggest that stratification of IBD using clinical EIM phenotypes may offer a strategy to define markers of disease that will improve diagnostic and therapeutic approaches to IBD.
Although a mechanistic understanding of the link between intestinal inflammation and SpA has yet to emerge, notable alterations in the intestinal microbiome of IBD patients compared to non-IBD controlsincluding a consistent reduction in taxa diversity and expansion of Enterobacteriaceae in new onset CD (10)-have implicated a role for the microbiome as the antigenic stimulus driving systemic inflammation. Seminal work supporting a role for the microbiome in systemic arthritis was performed using human lymphocyte antigen (HLA)-B27 transgenic rats that develop both spontaneous intestinal inflammation and arthritis (11) . Animals reared under germ-free conditions failed to develop inflammatory disease, whereas the reintroduction of normal luminal bacteria (including Bacteroides spp.) was sufficient to trigger inflammation (12) . Consistent with a role for intestinal microbiota in these animal models, early studies in ankylosing spondylitis (AS) patients observed an increased frequency of Klebsiella pneumoniae in fecal samples (13) coupled with cellular and humoral immunity to K. pneumoniae antigens (14) . More recent studies using current technology for microbial sequencing have defined unique microbial communities in inflammatory arthritis, including distinct microbiomes in AS (15) and rheumatoid arthritis (16, 17) . Recent characterization of the microbiome in psoriatic arthritis revealed decreased bacterial diversity similar to that seen in active IBD (18) , but the microbiome in IBDassociated SpA has not been well characterized.
Compositional analysis of the microbiome does not necessarily reflect the impact of the microbiome on host immunity. To address this limitation, a recently developed technique, which couples the sorting 1 of immunoglobulin A (IgA)-coated microbiota with 16S ribosomal RNA (rRNA) sequencing (called IgA-seq), focuses analysis on microbiota identified by the immune system (19) . These analyses highlight the dominant IgA response to keystone species, such as segmented filamentous bacterium (SFB) in mice, that make up a small fraction of the total microbiome yet exert a profound effect on IL-23-and T helper 17 cell (T H 17)-dependent mucosal and systemic immunity (20, 21) . Recent studies in both mouse models (22) and humans (19, 23) revealed the ability of IgA-coated microbiota to serve as pathosymbionts that can exacerbate disease phenotype. Fecal samples from IBD patients have increased levels of IgA-bound microbes (24) . Moreover, systemic seroreactivity to microbial-derived antigens in patients with CD (25) suggests active immunorecognition of microbial dysbiosis; however, the functional immune relevance of the IBD microbiome to disease phenotype is still emerging.
Although a causative microbe has not been identified in IBD, clinical cohorts consistently report the expansion of Enterobacteriaceae in active CD (10, (26) (27) (28) . These Enterobacteriaceae include a unique pathotype of Escherichia coli designated as adherent-invasive E. coli (AIEC) (29) . Although these AIEC strains lack virulence factors associated with diarrheagenic E. coli, they can adhere to and invade cultured intestinal epithelial cells and replicate in macrophages (30, 31) . Genetically, AIEC resemble extraintestinal pathogenic E. coli and harbor genes (including pduC and lpfA) that have been linked to invasion and intracellular persistence (32, 33) .
Given the overlapping genetic variation in the IL23R locus in both IBD (8) and SpA (9) cohorts, IL-23-responsive lymphocytes may underlie a potential shared immunopathogenesis. A large component of these IL-23-responsive lymphocytes are CD4
+ T H 17 cells that express the transcription factor RORgt, produce the cytokine IL-17, and play a critical role in promoting homeostasis at the mucosal barrier (34); however, in genetically susceptible animal models, microbial activation of T H 17 cells by the mouse commensal SFB (21, 35) is sufficient to drive pathogenic systemic inflammation (20, 36) .
Here, we investigated the hypothesis that functional analysis of the endogenous IgA-bound microbial repertoire in IBD-SpA will both stratify disease phenotype and provide insight into the immunopathogenesis. Compositional and functional analysis of the gut microbiome identified a significant expansion of IgA-coated E. coli, genotypically and functionally characterized as AIEC. Given our findings of systemic T H 17 activation in patients with CD-SpA reported here, gnotobiotic mice and mouse models of systemic T H 17-dependent inflammatory arthritis were used to evaluate the role for CD-SpA-derived E. coli in linking mucosal and systemic immunity.
RESULTS

Clinical and microbial parameters define CD-associated peripheral SpA
To test the hypothesis that clinical and microbial biomarkers correlate with IBD-SpA, we established a prospective cohort of 59 IBD patients with or without peripheral SpA [defined by the Assessment of SpondyloArthritis international Society (ASAS) criteria]. To control for microbiome alterations associated with disease activity, antibiotic exposure, and intestinal surgery, we only included patients with active disease [defined by Harvey-Bradshaw Index (HBI) > 4 or modified UC-DAI (disease activity index) > 2], who were off antibiotics for at least 8 weeks, and with an intact ileocecal valve (table S1). Only CD patients with ileal or ileocolonic disease (L1 or L3 disease by Montreal classification; table S2) were included to target a clinical phenotype previously associated with changes in the microbiome (27) . Furthermore, all patients were HLA-B27
− to avoid potential overlap with axial SpA. Groups were matched for age, sex, body mass index, and intestinal disease activity indexes (table S1) . To evaluate the clinical utility of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-a six-question, patientreported, clinically validated tool for assessing disease activity in AS (37)-in identifying joint inflammation in IBD-associated peripheral SpA, we recorded BASDAI scores for all patients at time of sample collection. BASDAI differentiated SpA from non-SpA for both CD and UC (Fig. 1A and table S1 ). Using a cutoff of >4 to indicate disease, BASDAI provided 83% specificity compared to the ASAS-defined diagnosis (38) . In contrast, no significant differences were observed between the cohorts in conventional serologic markers of disease activity including erythrocyte sedimentation rate, complement-reactive protein, vitamin D level, and hemoglobin.
To determine whether differences in the intestinal microbiota segregate individuals with IBD compared to IBD-SpA, we performed 16S rRNA sequencing of fecal DNA (all samples sequenced with >6500 reads per sample; fig. S1A ). Although the a-diversity metrics [including operational taxonomic units (OTUs) observed, Chao1, and Shannon entropy] revealed a contraction in diversity in CD compared to UC samples (fig. S1B) similar to previous reports (27) , no differences in diversity were noted between SpA and non-SpA groups ( fig. S1B ). Subjects were clustered using principal coordinate analysis (PCoA) with Bray-Curtis distances, which showed significant differentiation between CD and UC cohorts (P = 0.03), but no significant segregation between SpA and non-SpA groups (P = 0.17; Fig. 1B ). The most discriminative axis largely reflected the abundance of Proteobacteria in these samples. Composite phyla and family-level relative abundances revealed an expansion of Proteobacteria and Enterobacteriaceae, respectively, in subjects with CD-SpA compared to CD (Fig. 1C) . No differences in specific taxa were observed between UC and UC-SpA cohorts. Although analysis of genus-level relative abundances did not reveal any differences between CD and CD-SpA, linear regression analysis of BASDAI and relative bacterial abundance in patients with CD-SpA revealed a positive correlation with both Proteobacteria and Enterobacteriaceae abundance (Fig. 1D) . Increase in Proteobacteria abundance has been reported to correlate with intestinal disease severity in new onset CD (10, 30) ; however, in this cohort of patients with active L1/L3 CD, intestinal disease activity as measured by HBI was not sufficient to map this correlation by linear regression (Fig. 1E) . Although we used rigorous exclusion criteria to limit confounders, immunomodulator therapy varied in our patient cohort. Stratification by immunomodulator therapy (including thiopurines and biologics) did not account for differences in a diversity, b diversity, or taxonomic abundances in either CD or UC ( fig. S2 ).
IgA-seq reveals immunoreactive E. coli in CD-SpA Although our compositional analysis revealed differential abundance of microbial communities, these analyses do not necessarily reflect the immunological impact of these microbiota. Moreover, although no significant differences in genus-or taxa-level abundance between CD and CD-SpA cohorts were seen in our compositional analysis, we hypothesized that distinct immunologically reactive microbiota differentiate CD-SpA. To detect microbiota eliciting an immune response, we labeled and sorted IgA-coated (IgA + ) and noncoated (IgA − ) bacteria from fecal homogenates of CD patients profiled above (IgA-seq; Fig. 2A ). Similar to previous reports (19) and consistent with a recent report
Transl. Med. 9, eaaf9655 (2017) 8 February 2017 suggesting that IgA responses primarily target commensal bacteria of the small intestine (39), the proportion of intestinal bacteria coated with IgA was increased in CD compared to healthy donors; however, no significant difference was seen in IgA coating between CD-SpA and CD (Fig. 2B) . Of the 40 CD samples used for 16S rRNA sequencing, 30 samples (14 CD and 16 CD-SpA) were available for IgA-seq. Rarefaction at a sample depth of 1100 reads per sample left 23 samples (10 CD and 13 CD-SpA) for subsequent analysis ( fig. S3 ). Similar to compositional analysis, evaluation of the presort population also revealed significantly increased relative abundance of Proteobacteria in CD-SpA compared to CD, but no significant differences at the genus level were observed ( fig. S4 ). Although we did not observe significant differences in a-or b-diversity between IgA − and IgA + microbial community ( fig. S5 ), subject-level variance dominated PCoA analysis of b-diversity (P = 0.001; fig. S5B ). Analysis of the differential relative abundance of taxa at the phylum, family ( fig. S6 ), and genus level (Fig. 2C ) from the IgA − and IgA + microbial communities revealed significant enrichment of Escherichia/ Shigella in the IgA + fraction of patients with CD-SpA. To identify bacteria enriched in either the IgA + or IgA − fraction in CD, CD-SpA, or both, we used an average IgA-coating index (ICI) (23) of >0.1 or <−0.1, respectively (Fig. 2D) . The ICI analysis revealed enrichment of Eubacterium coprostanoligenes in the IgA + fraction from both CD and CD-SpA; however, similar to the analysis of the relative abundance data, only Escherichia/Shigella ICI score revealed differential enrichment in the IgA + fraction of CD-SpA. Pseudomonas (CD-predominant), For all panels, CD, n = 15; CD-SpA, n = 25; UC, n = 10; UC-SpA, n = 9. Eubacterium hallii (CD-predominant), Lachnospiraceae UCG008 (CD and CD-SpA), and Clostridium sensu stricto (CD-SpA-predominant) were enriched in the IgA − fraction. Escherichia/Shigella ICI linearly correlated with joint disease activity measured by BASDAI for patients with CD-SpA but did not correlate for patients with CD alone (Fig. 2E ).
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CD-SpA E. coli isolates are AIEC and initiate epithelial immunity To determine the pathotype of the IgAcoated E. coli in CD-SpA, we generated patient-derived isolates from three CDSpA donors with the highest Escherichia ICI score. Random amplified polymorphic DNA polymerase chain reaction (PCR) identified 15 unique isolates from these three CD-SpA-derived libraries (table S3) . PCR for phylogroup and key microbial virulence-associated genes revealed hierarchical clustering of all of these isolates with phylogroup B2 mouse (NC101) and CD-derived (LF82) AIEC isolates compared to a CD-derived non-AIEC E. coli strain (T75) ( Fig. 3A and table S3) (30) . E. coli clones were also derived from the IgAcoated fraction from three CD patients with the highest ICI score. Virulenceassociated genes were less frequent in CD-derived isolates including pduC, which was present in 11 of 15 CD-SpA-derived isolates, but only 4 of 15 CD-derived isolates (table S3) . Functional analysis of all CD-SpA-derived isolates revealed a high level of adherence and invasion of Caco-2 monolayers as well as persistence after macrophage invasion in vitro, consistent with their characterization as AIEC (Fig. 3 , B and C, and fig. S7 ). The complete genome of the B2 phylotype, CD-SpA-derived E. coli isolate 2A, which is used in subsequent experiments, was sequenced using Pacific Biosciences and assembled de novo into three contigs. The complete circular genome was 4,991,385 base pairs in length and most closely aligned to prototypical AIEC LF82 ( fig. S8) .
To evaluate the function of a representative CD-SpA-derived E. coli isolate 2A in vivo, we colonized 6-to 8-week-old germ-free C57BL/6 mice with E. coli 2A and assessed colonization by quantitative PCR (qPCR) 10 days later ( fig. S9A ). Similar to previous studies, AIEC did not induce overt intestinal disease in gnotobiotic C57BL/6 mice despite robust colonization (fig. S9B); however, real-time PCR of the terminal ileum epithelium revealed induction of resistin-like b (Retnlb) and serum amyloid A1 (SAA1) (Fig. 3D) , consistent with adhesion to the epithelial surface (21) . To directly assess attachment to the epithelium in vivo, we performed fluorescence in situ hybridization (FISH) of the terminal ileum 5 days after colonization (Fig. 3E) . Although CD-derived non-AIEC E. coli control T75 did not (E) Correlation between ICI and clinical joint disease activity (BASDAI) is shown for both CD (square) and CD-SpA (orange circle). Linear regression analysis reveals a significant correlation for CD-SpA (P = 0.03). For (C) to (E), CD, n = 10; CD-SpA, n = 13. penetrate the mucus layer, CD-SpA E. coli 2A was broadly adherent to the epithelial mucosa.
CD-SpA-derived AIEC promote mucosal T H 17 immunity
To evaluate the ability of CD-SpA-derived AIEC to promote T H 17 mucosal immunity, we colonized 6-to 8-week-old germ-free C57BL/6 mice with E. coli 2A. At 10 days after colonization, the production of IL-17 was higher in colonic CD4 + T cells from E. coli 2A-colonized mice compared to a non-AIEC control T75 (Fig. 4, A and B (Fig. 4D) ; however, E. coli 2A induced significantly more Foxp3 − RORgt CD4 + T cells (Fig. 4E ). E. coli 2A induced T H 17 polarization in the small intestinal lamina propria to a similar level seen after monocolonization with SFB ( fig. S10, A and B) . Finally, to evaluate the ability of isolate 2A to induce T H 17 immunity under non-gnotobiotic conditions, we challenged SFB-negative C57BL/6 weanlings with isolate 2A or T75. Similar to the monocolonization experiments, colonization with isolate 2A was sufficient to induce RORgt CD4 + T cells compared to animals colonized with T75 ( fig. S10C ). Thus, even in the presence of other commensal microbiota, CD-SpA-derived AIEC isolates induced robust T H 17 polarization.
In addition to T H 17 cells, group 3 innate lymphoid cells (ILCs) also respond to IL-23 and produce IL-22 (41) . To investigate the effect of E. coli isolate 2A on ILCs, we profiled colonic, lineage-negative, CD127
+ innate lymphocytes by intracellular cytokine staining after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation. E. coli 2A induced significant IL-22 production by ILCs, but no significant change in IFN-g production was observed (Fig. 4F and fig. S11, A To evaluate the ability of additional CD-SpA-and CD-derived E. coli isolates to induce T H 17 polarization, we used CD-SpA-derived isolates I2, C3, and 2A as well as CD-derived isolates L10, S7, and B4 (table S3) to colonize germ-free C57BL/6 mice. At 10 days after colonization, both isolate 2A (CD-SpA) and C3 (CD-SpA) induced significantly more T H 17 polarization compared to control non-AIEC E. coli T75 (Fig. 4G) . No significant induction of T H 17 was observed after colonization with CD-derived isolates or CD-SpA isolate I2. Notably, isolate 2A and C3 both contain AIEC virulence-associated genes, including iroN, ratA, and pduC (table S3) , which are not present in isolate I2, suggesting that genetic heterogeneity impacts the effect on mucosal immunity.
Recent reports suggest that mucosal adherence is a critical feature in microbial induction of T H 17 cells (42, 43) . Genetic deletion of the Intimin gene (eae), essential for epithelial attachment of Citrobacter rodentium and Enterohemorrhagic E. coli O157, resulted in decreased induction of T H 17 (42) . Although eae is not present in AIEC, pduC, which encodes the large subunit of propanediol dehydratase, allows AIEC to forage within the mucus layer using fucose-derived propanediol as an alternate carbon source and provides a competitive metabolic advantage for epithelial adherence (33, 44) . To evaluate the role for pduC in AIEC induction of intestinal T H 17 cells, we generated pduCdeficient (DpduC) AIEC using the l red recombinase system (33) in a mouse-derived AIEC CUMT8, which only contains virulence-associated factors lpf and pduC. Similar to isolates 2A and C3, colonization with CUMT8 induced robust T H 17 polarization (Fig. 4, H and I) . At 10 days after colonization, all strains efficiently and equivalently colonized the intestine (fig. S13) ; however, deletion of pduC resulted in a significant decrease in colonic T H 17 induction, which was restored with genetic complementation (DpduC + pduC) (Fig. 4, H and I) . Although the presence of pduC alone was not sufficient to promote T H 17 cell induction in CD-derived isolates lacking additional virulence factors (Fig. 4G) , these results identify pduC as a critical component of AIEC's capacity to induce T H 17 barrier immunity.
IL-10 and IL-23 regulate the effects of CD-SpA AIEC in DSS-induced colitis Although colonization of wild-type (WT) germ-free mice did not induce intestinal histopathological abnormalities ( fig. S9B) , we sought to evaluate the effect of colonization with CD-SpA E. coli 2A during colitis. Recent data suggest that lymphoid tissue-resident commensal bacteria, which promote both T H 17 and ILC3 immunity, protect host tissue from dextran sulfate sodium (DSS) via IL-10 (45). To test the protective ability of CD-SpA-derived AIEC, we induced colitis with DSS in 6-to 8-week-old gnotobiotic C57BL/6 mice monocolonized with CD-SpA E. coli 2A or control media. Whereas germ-free mice rapidly and uniformly succumbed to DSS-induced colitis by day 9, E. coli 2A and T75 colonization were sufficient to rescue these mice ( fig. S14 ). qPCR analysis of Il10 expression in lamina propria mononuclear cells from monocolonized mice revealed a significant increase in gnotobiotic mice colonized with isolate 2A compared to T75 (Fig. 5A) . To evaluate the role for this IL-10 induction in regulating the balance of T H 17 immunity, we colonized germ-free IL-10-deficient mice with E. coli 2A or control media. In the absence of IL-10, we found a significant reduction in the RORgt/Foxp3 + CD4 + T cells and a more robust induction of T H 17 cells and IL-17/IFN-g-producing CD4
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+ T cells (Fig. 5B) . Although no spontaneous colitis or histological effect was seen at the basal state [consistent with the resistance of IL-10-deficient mice on a C57BL/6 background to develop spontaneous colitis (46) ], exposure of IL-10-deficient mice to DSS after colonization with E. coli 2A resulted in reduced survival compared to those mice gavaged with media or non-AIEC T75 (Fig. 5C) . DSS-treated IL-10-deficient mice colonized with E. coli 2A developed more severe colonic inflammation compared to noncolonized controls or mice colonized with non-AIEC E. coli isolate T75 (Fig. 5D ). Similar to basal state analysis, colonization with E. coli 2A before DSS-induced colitis resulted in increased production of both IL-17 and IL-17/IFN-g + CD4 + T cells (Fig. 5E ). These findings support the notion that CD-SpA E. coli 2A, like other AIEC, is a pathosymbiont that can opportunistically drive intestinal inflammation in a genetically susceptible host.
Although DSS-induced colitis is considered a non-T cell-dependent colitis, IL-23 contributes to disease severity in a T cell-sufficient animal (47) . To assess the contribution of IL-23-dependent colitis in our IL-10-deficient model, we treated the mice with anti-IL-23 blocking antibody after induction of colitis with DSS. IL-23 blockade rescued the mice from the reduced survival (Fig. 5F ), and blockade resulted in a reduction in both IL-17 and IL-17/IFN-g + CD4 + T cells (Fig. 5G) . Collectively, in the genetically susceptible IL-10-deficient background, CDSpA-derived AIEC promote IL-23-dependent inflammatory colitis.
Intestinal colonization with CD-SpA-derived AIEC induces systemic T H 17 immunity and promotes joint inflammation An increase in T H 17 cells has been shown in CD patients with active ileal disease (48, 49) . To evaluate mucosal T H 17 cells in patients with CD-SpA, we phenotyped CD4 + T cells in ileal biopsies from patients with CD or CD-SpA undergoing endoscopic evaluation with active ileitis. Analysis of cytokine expression revealed a significant increase in IL-17 production from patients with CD-SpA compared to CD alone (Fig. 6A) . No differences were seen in the expression of Foxp3 or IFN-g levels. To evaluate systemic immunity in our patient cohort, we measured inflammatory serum cytokine levels. Targeted multiplex analysis of inflammatory cytokines revealed a significant increase in IL-17A and IFN-g, but no difference in tumor necrosis factor-a (TNFa) were observed (Fig. 6B) . These mucosal and systemic data reveal a T H 17 immunophenotype in our CD-SpA cohort.
To evaluate the systemic recognition of luminal AIEC in patients with CD-SpA, we determined IgG seroreactivity to E. coli antigens. As previously described (50), the binding of total serum IgG from patients with or without SpA to E. coli was evaluated by flow cytometry. Patients with CD-SpA showed increased, titratable IgG seroreactivity to E. coli antigens but no increased reactivity against Bacteroides, in comparison to matched CD controls (Fig. 6C) . This specific systemic seroreactivity to E. coli antigens supports the potential role for AIEC in breaking the compartmentalization of the intestinal immune response to luminal microbes and promoting systemic T H 17 immunophenotype in CD-SpA.
Given the systemic T H 17 activation observed in CD-SpA, we sought to evaluate the ability of CD-SpA isolate 2A to support systemic T H 17 immunity in vivo. To test whether colonization with E. coli 2A induces systemic immunity, we evaluated the induction of antigen-specific splenic CD4 + T cell response by ELISPOT after monocolonization 
Viladomiu et al., Sci. Transl. Med. 9, eaaf9655 (2017) 8 February 2017 in C57BL/6 mice. Similar to SFB, colonization with E. coli 2A primed a systemic, antigen-specific T H 17 response (Fig. 6D) . To evaluate whether colonization with E. coli 2A was sufficient to induce inflammatory arthritis, we used a mouse model of arthritis (K/BxN) (20) . Previous reports have shown the dependence of this model on T H 17 cell induction and demonstrated the sufficiency of T H 17-inducing microbiota to support disease. To test the sufficiency of E. coli 2A in promoting inflammatory arthritis, we colonized SPF K/BxN mice with E. coli 2A, and ankle thickness was measured after colonization. Within 6 days, significant differences in ankle thickness were apparent and increased up to 10 days after colonization (Fig. 6E ). Similar to colonization in gnotobiotic mice, we noted significant T H 17 cell expansion in both the spleen and small intestinal lamina propria compared to controls (Fig. 6 , F and G). Colonization with CD-SpA E. coli 2A led to an increase in IgA + B cells in both the spleen and Peyer's patches (Fig. 6, H and I ), IgG1 + GC B cells in the spleen (Fig. 6J) , and anti-GPI titers (Fig. 6K) compared to T75 control. Collectively, these data support the ability of IgA-coated AIEC that are enriched in patients with CD-SpA to support systemic T H 17 inflammatory disease.
DISCUSSION
The immunologic relevance of compositional changes in the microbiome to disease phenotype remains a major question in the study of human disease. Initial studies introducing new approaches to identify immunogenic components of the microbiome, including IgA-seq (19) and BugFACS (23), identified intestinal pathosymbionts within a microbial community that promote disease under specific genetic or environmental circumstances. Our identification here of IgA-coated E. coli as a pathosymbiont in CD-SpA shows that these technologies can be applied more broadly to help stratify complex clinical phenotypes, particularly those in which antigenic stimuli from the intestine are thought to be a key component. Although previous studies in HLA-B27 transgenic rats and mouse models revealed a role for luminal microbes in supporting systemic inflammatory arthritis, our results now identify AIEC as a pathosymbiont in CD-associated SpA.
Our analysis identified the enriched IgA-coated E. coli in CD-SpA as an AIEC pathotype, but AIEC are present in the microbiome of healthy controls and CD patients without SpA. Our experimental models highlight two features of the host-pathogen interaction that must be considered to understand the specificity of pathogenetic mechanisms of AIEC in SpA, namely, host susceptibility and strain variability.
First, although the microbial activation of the IL-23 pathway plays a critical role in maintaining homeostasis and promoting mucosal healing, T H 17 cell activation may act as a double-edged sword by promoting the inflammatory response in cases of environmental or host genetic susceptibility to inflammatory disease (47) . Similar to SFB protection from C. rodentium-induced colitis (21) or lymphoid tissue-resident commensal bacteria protection from DSS-induced colitis (45) , CDSpA-derived AIEC protect against acute injury and death from DSSinduced colitis in WT mice. Resident microbiota, including AIEC, induce colonic RORgt/Foxp3 + CD4 + T cells, which play an important role in restraining inflammatory colitis (40) . Consistent with the protective effect illustrated by our data, a higher Enterobacteriaceae ICI in 6-month-old infants correlated with better nutritional status (23) . Thus, in situations of nutritional sufficiency or immunocompetence, the response to Enterobacteriaceae may have coevolved to protect the host; however, persistent nutritional deficiency (23) or genetic susceptibility (modeled in IL-10-deficient and K/BxN mice) evokes maladaptive responses, which, in turn, promote more severe inflammatory T H 17 disease. Likewise, our data link the shared genetic susceptibility in the IL23R locus in both CD and SpA (9) with increased systemic E. coli seroreactivity and T H 17 inflammatory cytokines. With the recent approval of IL-23 blockade therapy for CD, the clinical phenotype of peripheral SpA may help stratify an immunophenotype in a susceptible host that may benefit from targeted anti-IL-23 therapy.
Second, unique strain-specific features of epithelial cell attachment are critical in dictating the immune outcome. Epithelial cell attachment is a critical feature of the mouse commensal SFB and is required to induce T H 17 immunity (42) . A recent report, which identified the ability of the human commensal Bifidobacterium adolescentis to induce T H 17 cells, similarly requires attachment to the intestinal epithelium despite triggering epithelial transcriptional changes distinct from those induced by SFB (51) . In human fecal samples, PCR detection of virulence genes eae and aggR required for adherence of enteropathogenic and enteroaggregative E. coli, respectively, identified individuals with a higher Enterobacteriaceae ICI and impaired nutritional status (23) . eae-dependent attachment to the epithelial cell barrier is a critical determinant of T H 17 induction by C. rodentium and Enterohemorrhagic E. coli O157 (42) . CD-SpA-associated E. coli are distinct from Enteropathogenic E. coli and C. rodentium in that they lack type III secretion system effectors (including eae), and aggR associated with diarrheagenic Enterobacteriaceae; however, most of the CD-SpA E. coli isolates expressed the AIEC virulence-associated gene pduC. The metabolic advantage provided by propanediol dehydratase promotes epithelial cell adhesion seen in both clinical and environmental AIEC isolates containing pduC (33, 44) . This requirement of pduC for AIEC induction of T H 17 cells in the lamina propria offers a potential targetable link of microbial metabolic capacity to T H 17-dependent mucosal immunity.
Despite the role of pathosymbionts, such as AIEC, as keystone species, dynamic interactions with other commensals may modulate the immunopathology. In mouse models of gut barrier disruption, diverse microbial community members, including Bacteroidetes, were required for the pathogenic effect of Enterobacteriaceae isolated from nutritionally deficient individuals, whereas Akkermansia is protective (23) . The outcome of these microbial interactions may depend on environmental context. Although reduced levels of Akkermansia muciniphila in both IBD and metabolic disease (52, 53) support an anti-inflammatory role for this mucin-degrading microbe, recent data revealed a positive correlation of A. muciniphila ICI with arthritis severity in the HLA-B27 rat model (22) . The interaction of AIEC with other intestinal pathosymbionts may offer a more complete understanding of its impact on mucosal immunity and inflammation.
Our study has important limitations. First, our immunophenotype and microbiome results reflect findings in an HLA-B27
− peripheral IBD-SpA cohort. Despite increased IL-23 in intestinal tissue, previous reports of axial SpA did not show an increase in ileal IL-17 (54).
Moreover, HLA-B27 has been reported to alter the intestinal microbiome (55) , and further studies are needed to evaluate the microbiome in HLA-B27 + axial and peripheral IBD-SpA. Second, no compositional changes were noted between UC and UC-SpA patients suggesting that other environmental or genetic factors may account for peripheral SpA in UC. Third, strain variability even within AIEC isolates can be diverse. Although our analysis primarily reflects colonization with CD-SpA isolate 2A and shows dependence on pduC, additional isolates and genetic elements may also contribute to systemic T H 17 inflammatory disease. Finally, our study does not address the immune response within the inflamed joint. Although previous studies have highlighted a potential role for molecular mimicry in microbial induction of SpA (56) , indirect support of alternative IL-23-dependent immune effector cells (57) still need to be characterized in IBD-SpA.
These results highlight the functional implication of IgA-coated E. coli enriched in CD-SpA and identify a T H 17 immunophenotype characteristic of this EIM. This mechanistic link between intestinal microbiota and systemic inflammation may underlie the clinical efficacy of sulfasalazine in peripheral joint symptoms (58) . While anti-TNFa therapy improves axial symptoms in patients with active CD (59), our data highlight the activation of the IL-23/IL-17 pathway in CD patients with peripheral symptoms. Although blockade of IL-17A yielded disappointing results in the overall treatment of CD, the lack of clinical response correlated with the absence of polymorphisms in genes associated with T H 17 immunity (60) . With the recent approval of anti-IL-23 therapy for CD, our data now offer a method of clinical, microbial, and immunophenotyping of CD-SpA that can be used to guide precision medical and biologic therapy.
MATERIALS AND METHODS
Study design
A prospective cohort of IBD patients was evaluated for SpA at the Jill Roberts Center for IBD under Institutional Review Board-approved protocol (1103011578) at Weill Cornell Medicine (WCM). The overall objective of this observational study was to determine differences in microbial composition in IBD patients with SpA compared to IBD patients without SpA. On the basis of preliminary and published data, 25 subjects per group were required to detect a 10% difference relative abundance of Proteobacteria. Subjects between the ages of 18 and 80 with biopsy-proven active ileal or ileocolonic (CD, HBI > 4) or UC (modified UC-DAI > 2), with or without clinical evidence of peripheral SpA assessed by a rheumatologist (according to the ASAS guidelines) (61), were recruited. All subjects were free of other rheumatic disease, HLA-B27 − , and off antibiotics (including sulfasalazine) for at least 8 weeks at enrollment and had an intact colon and ileocecal valve. All patients completed the BASDAI-a clinically validated exam for disease activity in AS (37)-and a 44-point joint assessment. Fresh fecal samples and serum were obtained and stored at −80°C until further analyses. For patients undergoing endoscopic evaluation, cells isolated from mucosal biopsies were obtained and stored at −160°C until further analyses. Sequencing and immune cell analyses were performed blinded with respect to patient phenotype.
BugFACS
As previously described (19) , 100 mg of fecal contents was homogenized in phosphate-buffered saline (PBS) on ice. Clarified supernatants were washed in PBS/1% bovine serum albumin and incubated with blocking buffer (20% normal mouse serum in PBS) for 20 min. Samples were subsequently stained with mouse anti-human IgA (IS11-8E10) or isotype (Mouse IgG1) and sorted on FACS Aria (BD Biosciences). Samples were costained for nucleic acids with SYTO BC (Invitrogen).
Animal models
Mice. Germ-free C57BL/6 WT and IL-10 −/− mice were bred and maintained at WCM. K/BxN mice were generated by crossing KRN TCR transgenic mice on the B6 background with nonobese diabetic mice and maintained at the University of Arizona. All treatments were in accordance with WCM and the University of Arizona Institutional Animal Care and Use Committee guidelines. Colonization of germ-free mice.
For monocolonization experiments, 6-to 8-week-old germ-free mice were gavaged with 2 × 10 9 CFU log-phase bacteria grown under anaerobic conditions in peptone yeast glucose liquid media (Anaerobe Systems). 16S rRNA qPCR of fecal content-and cecal content-derived DNA was used to confirm colonization. For K/BxN colonization experiments, 3-week-old SPF K/BxN mice were treated with ampicillin (1 g/liter), neomycin (1 g/liter), and metronidazole (1 g/liter) for 10 days. After a 1-day washout, the mice were then gavaged with media or 2 × 10 9 CFU of AIEC 2A daily for 3 days. Ankle thickness was measured daily after bacterial gavage, and tissues were collected 10 days after bacterial challenge for flow cytometry analysis.
Statistics
Analysis and visualization of microbiome communities was conducted in R, using the phyloseq package (62) to import sample data and calculate a-and b-diversity metrics. For microbiome analysis, significance of relative abundance was calculated using the nonparametric MannWhitney test. Principal coordinate plots used the Monte Carlo permutation test to estimate the P values. All P values were adjusted for multiple comparisons with the false discovery rate algorithm. Correlation between two continuous variables was determined with linear regression models, where P values indicate the probability that the slope of the regression line is zero. Significance of categorical variables, such as gene expression, cell populations, or histology, was calculated by t test for comparison of two groups and two-way ANOVA for comparison of more than two groups. The significance of survival curves was determined by log-rank test.
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